Javier Cortés - Researcher Profile | RDL Research Database

Publications

4 shown

Pembrolizumab for Early Triple-Negative Breast Cancer

Peter Schmid , Javier Cortés , Lajos Pusztai +18 more

Among patients with early triple-negative breast cancer, the percentage with a pathological complete response was significantly higher among those who received pembrolizumab plu...

2020 New England Journal of Medicine 2718 citations

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Javier Cortés , David W. Cescon , Hope S. Rugo +97 more

2020 The Lancet 1658 citations

Breast cancer

Nadia Harbeck , Frédérique Penault‐Llorca , Javier Cortés +6 more

2019 Nature Reviews Disease Primers 2678 citations

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer

Shanu Modi , Cristina Saura , Toshinari Yamashita +22 more

Trastuzumab deruxtecan showed durable antitumor activity in a pretreated patient population with HER2-positive metastatic breast cancer. In addition to nausea and myelosuppressi...

2019 New England Journal of Medicine 1788 citations

Frequent Co-Authors

Researcher Info

h-index: 4
Publications: 4
Citations: 8,842
Institution: Vall d'Hebron Institute of Oncology

External Links

ORCID Profile Google Scholar

Identifiers

ORCID: 0000-0001-7623-1583

Impact Metrics

h-index 4

h-index: Number of publications with at least h citations each.